Autologous reconstitution is the recovery of autologous hematopoietic function after failure of an allogeneic graft to establish sustained hematopoiesis either with or without preceding donor engraftment. We reviewed 9 years experience of the University of Minnesota and identified 10 of 291 patients who underwent allogeneic BMT for Ph-positive CML and developed non-leukemic autologous reconstitution. All patients received the same preparative regimen with cyclophosphamide and total body irradiation. Eight patients had a 6/6-antigen matched donor. Eight patients received their graft from an unrelated donor. In five cases the graft was T celldepleted. Non-malignant autologous reconstitution initially manifested as mixed chimerism in nine of 10 patients and lasted for a median of 11 (3-41) months. Eight patients have relapsed and four are still alive. The two relapse-free patients have died 24 and 48 months post transplant. Of the four surviving patients, two are in interferon-induced cytogenetic remission at 53+ and 101+ months of follow-up. Autologous non-leukemic reconstitution is uncommon, but appears to be a distinct clinical syndrome, perhaps occurring more frequently after unrelated donor BMT. Although usually followed by relapse, relapse-free survival may be prolonged.
predispose to graft failure, [1] [2] [3] [4] [5] [6] although clinical factors that lead to autologous reconstitution are unknown. Several case reports describe patients with autologous reconstitution who did not progress to relapse, a few of whom had apparently prolonged disease-free survival. [7] [8] [9] [10] [11] [12] The incidence and clinical significance of autologous reconstitution is still uncertain. To assess the frequency and clinical outcome of patients with non-leukemic autologous reconstitution after allogeneic BMT for Ph-positive chronic myelogenous leukemia (CML) we reviewed 9 years (1988-1997) experience of the University of Minnesota BMT program.
Patients and methods

Patients
During the study interval, we identified 10 of 291 patients with Ph-positive CML who underwent an allogeneic BMT and subsequently developed Ph-negative, autologous hematopoietic reconstitution. Individual patient characteristics are shown in Table 1 . Seven of 10 patients were females and the median age was 26 years (range 11 months to 50 years). Eight patients were transplanted in first chronic phase, one in second chronic phase, and one in accelerated phase. Seven of the donor/recipient pairs were gender mismatched. All patients were conditioned with cyclophosphamide 60 mg/kg once daily intravenously (total dose 120 mg/kg), followed by total body irradiation 1320 cGy, in eight fractions, over 4 days. Graft characteristics for individual patients are listed in Table 1 . Eight patients received unrelated donor (URD) grafts. Six of these were phenotypically HLA-matched at HLA A, B, and DRB1; two patients had an HLA-mismatched graft (one at HLA B and one at HLA A and DR loci). Five patients received graftversus-host disease (GVHD) prophylaxis using T cell depletion through centrifugal counter-flow elutriation along with post-transplant cyclosporine. The others received short course methotrexate and cyclosporine. Acute GVHD was observed in five patients and one developed chronic GVHD (Table 1) .
Autologous recovery was diagnosed when over 25% of recipient non-leukemic hematopoiesis was apparent using restriction fragment length polymorphism (RFLP) to quantitate donor vs recipient DNA in BM aspirate specimens. 
Post-transplant engraftment and chimerism studies
Post-transplant engraftment studies based on molecular genetic methods were used to assess the quantitative fraction of donor vs recipient hematopoiesis in serial samples of bone marrow (BM). Genomic DNA was obtained from patients and donors prior to transplant and evaluated for markers of identity by polymerase chain reaction. 13 In the post-transplant period, patient samples of bone marrow or blood were tested for the same markers to assess the origin of cells as either donor or recipient. These data are calculated as percent donor engraftment and reported in quartile increments. For this report, only BM samples were considered.
Cytogenetics
Cytogenetic evaluation for each patient consisted of Gbanded chromosomal analysis of a minimum of 20 metaphase cells, whenever possible, from unstimulated, cultured (24 h) bone marrow aspirates. All numerical and structural chromosomal abnormalities were characterized according to the ISCN, 1995.
14 Additionally, for patients with very hypocellular marrows, those with insufficient metaphase cells, or for patients with numerous complex structural abnormalities that might have obscured the detection of a t(9;22), fluorescence in situ hybridization (FISH) was performed on interphase cells using distinguishable fluorescent DNA probes for ABL and BCR.
Results
Nine of 10 patients had initial, but transient donor cell engraftment (Table 2) . A median of 85% (range 10-100%) peak donor cell BM engraftment was observed that lasted a median of 2 months (range 1 to 12 months). One patient (No. 2) never had any evidence of donor hematopoiesis and had non-leukemic autologous reconstitution identified by 1 month post BMT. In the other nine patients, autologous reconstitution was initially manifest as mixed chimerism, but progressed rapidly to complete loss of the donor graft in eight patients over 1 to 3 months (median 1 month) ( Table 2) . One patient (No. 10) had persistence of 25% donor hematopoiesis 12 months after developing autologous reconstitution until death secondary to refractory GVHD. For the group as a whole, this non-leukemic autologous reconstitution persisted a median duration of 11 months (range 3 to 41). The clinical outcome of individual patients is summarized in Table 2 and their clinical course is shown in Figure 1 . After 6 to 37 months of repeatedly assayed Phnegative hematopoiesis, eight patients developed cytogenetically and/or clinically documented relapse of CML (Table 3) . One patient (No. 6) remained in continuous complete clinical and cytogenetic remission for 48 months of follow up. However, after 12 months of autologous reconstitution she developed Ph-negative and Bcr/Abl-negative, clonal chromosomal abnormalities in autologous cells. The Six patients died 16 to 48 months (median 27 months) post BMT. Two patients died after relapse in blast crisis, three following a second BMT, and one of refractory GVHD.
Discussion
The possible consequences of graft failure after allogeneic BMT for leukemia include multilineage aplasia and transfusion dependency, autologous reconstitution or progression to leukemia relapse. The recovery of autologous hematopoiesis with no evidence of disease relapse is uncommon. We describe a group of 10 CML patients with transient engraftment (nine patients) or non-engraftment (one patient) who developed sustained non-leukemic autologous reconstitution that later evolved to cytogenetic and/or clinical relapse in eight patients. These patients have developed the equivalent of an endogenous, in vivo autologous transplant resulting in restoration of benign host hematopoiesis. Seven somewhat similar individual cases have been previously reported (Table 3) . [7] [8] [9] [10] [11] [12] All the reports include patients with CML and the majority were in chronic phase (five of seven patients) at the time of the transplant. One had Ph-negative CML.
T cell depletion of the allograft for GVHD prophylaxis has been associated with a higher incidence of mixed chimerism, graft failure, and relapse after allogeneic BMT. 1, 2, [4] [5] [6] Five of this series and three of seven patients from the literature received T cell-depleted grafts. 7, 10, 11 We hypothesize that the mechanism inducing prolonged suppression of residual host hematopoiesis, both benign and malignant, is a T cell-mediated donor anti-host and antileukemia effect. Circumstances that have been associated with more frequent graft failure (T cell depletion, unrelated or partially matched transplantation) might also be permissive for persisting host hematopoiesis and subsequent autologous reconstitution. This same defective graft-anti-host hematopoiesis effect could result in an attenuated graft-versus-leukemia effect and the higher rate of relapse observed.
Autologous reconstitution appears to develop early, at a median of 1 month in our series and 1.5 months combining the current patients with the published case reports. However, we observed only a brief duration of autologous reconstitution (median 11.5 months; range 3-41), while the other reported cases range from 13.5 to 108 months (median 59 months). [7] [8] [9] [10] [11] [12] Publication bias (reports of lengthier and thus more striking cases of autologous reconstitution) might account for this apparent difference. Alternatively, the presence of residual donor lymphoid activity may explain the prolonged remissions observed in some of these patients. However, there is yet no clinically available technique to demonstrate the persistence of a minor lymphoid effector cell population.
The clinical outcome of these patients is best predicted by the time to clinical relapse of leukemia. Those patients showing any sign of relapse within 1 year post transplant had a poor outcome and short post-transplant survival. Patients with more prolonged non-relapse autologous reconstitution (one to three years) had an intermediate prognosis while those with longer post-transplant remission (3+ years) enjoy a notably longer survival (Figure 1) .
MDS or other secondary malignancy is not described in the seven reported cases of non-malignant autologous reconstitution. An additional hazard of graft failure and deficient anti-host immune effects may be persistence and/or expansion of abnormal clones with resultant MDS. Two patients had neither cytogenetic nor clinical CML relapse but developed clonal abnormalities which include recurring structural and numeric rearrangements associated with MDS (del 7q, del 13q, +19, del 20q, +21). One patient (No. 6) developed clinically diagnosed MDS. Three additional patients had recurrent Ph-positive clones, but also had other Ph-negative clones containing the same MDS-associated rearrangements.
One possible approach to the development of autologous reconstitution is the infusion of donor lymphocytes. This can restore donor hematopoiesis and molecular remissions in up to in two-thirds of CML patients relapsed in chronic phase. [15] [16] [17] [18] The 3-year survival for these patients is estimated to be above 70%, 19 though, aplasia and GVHD are known complications of donor lymphocyte infusions, 15, 18, 19 These hazards must be considered in the decision as autologous reconstitution patients do not initially have leukemia relapse.
Autologous, non-leukemic reconstitution is uncommon, but appears to be a distinct clinical syndrome among CML patients that undergo allogeneic BMT. Although usually followed by relapse, patients can have extended survival with non-leukemic hematopoiesis. The utility of anti-leukemia strategies to extend this remission, such as alpha-interferon and donor lymphocyte infusions, needs further study.
